Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,125 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Injectable Clear all
Completed Phase 4 Interventional

The Kentucky Viral Hepatitis Treatment Study

NCT03949764
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders, Injection Drug Use
Interventions
Sofosbuvir/velpatasvir (Epclusa®)
Drug
Lead sponsor
Jennifer Havens
Other
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles

NCT03223298
View directory record Official record
Conditions
Pain, Head, Pain Syndrome, Temporomandibular Disorder, Myofascial Pain Syndrome, Myofascial Pain
Interventions
Botulinum toxin type A, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 21, 2026, 9:57 AM EDT
Recruiting No phase listed Observational

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

NCT05813678
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
Pegvaliase
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
12
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014635
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Jul 21, 2026, 9:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

SprmPik AI Sperm Selection Study SiD, an Assistant for Sperm Selection During Intracytoplasmic Sperm Injection in Medically Assisted Reproduction: Effect on Fertilization, Blastocyst Formation, Early Pregnancy Loss, and Consistent Practice. A Prospective Pilot Study.

NCT06518928
View directory record Official record
Conditions
Infertility
Interventions
Artificial Intelligence assisted sperm selection
Other
Lead sponsor
Ovation Fertility
Other
Eligibility
Not listed
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

NCT03429049
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
CNTX-4975-05, Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

FX-322 in Adults With Severe Sensorineural Hearing Loss

NCT04629664
View directory record Official record
Conditions
Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
Interventions
FX-322, Placebo
Drug · Other
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Novi, Michigan • Omaha, Nebraska • Amherst, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

NCT01523067
View directory record Official record
Conditions
Essential Hypertension
Interventions
Vasomera (PB1046), 0.9% Sodium Chloride
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

JUVÉDERM® VOLITE™ XC for Cheek Skin Smoothness

NCT03728309
View directory record Official record
Conditions
Skin Smoothness of the Cheeks
Interventions
JUVÉDERM VOLITE™ XC
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Fresno, California • Los Angeles, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Jul 21, 2026, 9:57 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Randomized Trial of Combination Treatment With Sofwave and Sculptra

NCT07342452
View directory record Official record
Conditions
Skin Aging
Interventions
Sofwave, Sculptra
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 21, 2026, 9:57 AM EDT
Terminated Phase 1 Interventional

Stem Cell Injection to Treat Heart Damage During Open Heart Surgery

NCT01557543
View directory record Official record
Conditions
Heart Disease, Ischemic Heart Disease, Coronary Artery Disease, Coronary Artery Disease (CAD)
Interventions
Cell Therapy
Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

NCT03005717
View directory record Official record
Conditions
Submental Fat
Interventions
LIPO-202, Placebo for LIPO-202
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional

Sterile Amniotic Fluid Filtrate Epidural Injection.

NCT04537026
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Amniotic Fluid Allograft, Dexamethasone sodium phosphate
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jul 21, 2026, 9:57 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries

NCT07080008
View directory record Official record
Conditions
Ureter Injury
Interventions
Lumitrace, KARL STORZ POWER LED BLUE System
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Recruiting Phase 2 Interventional

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

NCT06764940
View directory record Official record
Conditions
HER2-negative Breast Cancer Patients With Brain Metastases
Interventions
Utidelone, Utidelone in combination with capecitabine
Drug
Lead sponsor
Biostar Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Duarte, California • Los Alamitos, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 21, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

Hysteroscopic Lymphatic Mapping for Endometrial Cancer

NCT00671606
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Intraoperative Lymphatic Mapping
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Jul 21, 2026, 9:57 AM EDT
Completed No phase listed Observational

Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System

NCT02073058
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
No treatment
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 21, 2026, 9:57 AM EDT
Active, not recruiting Phase 4 Interventional

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana

NCT05986084
View directory record Official record
Conditions
Pre-Exposure Prophylaxis (PrEP), Breast Feeding
Interventions
Cabotegravir Injection [Apretude]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

NCT02328768
View directory record Official record
Conditions
Total Parenteral Nutrition-Induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jul 21, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jul 21, 2026, 9:57 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

NCT06171750
View directory record Official record
Conditions
Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Interventions
tolododekin alfa, Cemiplimab
Drug
Lead sponsor
Ankyra Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 9:57 AM EDT